Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Celldex Therapeutics Announces Upcoming Presentation at Leerink Swann Global Healthcare Conference 2013



Celldex Therapeutics Announces Upcoming Presentation at Leerink Swann Global
Healthcare Conference 2013

NEEDHAM, Mass., Feb. 11, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc.
(Nasdaq:CLDX) announced today that Anthony Marucci, President and Chief
Executive Officer, is scheduled to present a corporate overview at the Leerink
Swann Global Healthcare Conference 2013 on Wednesday, February 13, 2013 at
11:30 am ET at The Waldorf Astoria New York.

A live webcast of the presentation will be available online on the "Events &
Presentations" page of the "Investors & Media" section of the Celldex website.
A replay of the presentation will be available for 90 days following the
event.

About Celldex Therapeutics, Inc.
Celldex Therapeutics is the first antibody-based combination immunotherapy
company. Celldex has a pipeline of drug candidates in development for the
treatment of cancer and other difficult-to-treat diseases based on its
antibody focused Precision Targeted Immunotherapy (PTI) Platform. The PTI
Platform is a complementary portfolio of monoclonal antibodies,
antibody-targeted vaccines and immunomodulators used in optimal combinations
to create novel disease-specific drug candidates.

CONTACT: Sarah Cavanaugh
         Vice President of IR & Corp Communications
         Celldex Therapeutics, Inc.
         (781) 433-3161
         scavanaugh@celldextherapeutics.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement